CLINICAL TRIAL

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-06-12
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

COMPASS Pathways

Watch author

Topics and keywords

psilocybin PTSD Safety Other Post Traumatic Stress Disorder Psilocybin COMP360 COMPLETED

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-05-11 Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatmentEClinicalMedicine · 2025-11-30 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyClinicalTrials.gov · 2024-12-03 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-11-08 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-06-04 Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy SubjectsClinicalTrials.gov · 2025-03-04 PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)ClinicalTrials.gov · 2024-11-05 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-23